Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - News - Pharmaceutical Development - November 18, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/19/17 - 2nd gene therapy for blood cancer approved
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals. The treatment, called Yescarta, wi
10/19/17 - City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR-T Cell Therapy for Adult Patients with Certain Types of Large B-cell Lymphoma
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will be one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration announced today is the first approved CAR-T cell therapy for adult patients with certain types of large B-cell lym
10/19/17 - Family hoping for FDA approval of MD drug
Diagnosed with Duchenne muscular dystrophy when he was 2, Tommy Parzymieso, a 9- year-old Eggert Elementary student, has been battling the disease most of his life as his family seeks a drug to aid his fight against the progressive muscle-wasting condition. The meeting was held after PTC Therapeutics, the company that developed the drug, filed on t
10/19/17 - FDA approves new gene therapy for blood cancer
The U.S. Food and Drug Administration approved a new form of cell-based gene therapy for adults with certain types of large B-cell lymphoma, marking only the second time a gene therapy has been approved for the disease. The FDA said diffuse large B-cell lymphoma is the most common type of non-Hodgkin's Lymphona in adults and there are approximately
10/19/17 - Foundation Fighting Blindness gets new CEO [The Baltimore Sun]
Oct. 19 The Foundation Fighting Blindness announced Wednesday that it has named Benjamin Yerxa as its new CEO, effective immediately. He previously served as president and co-founder of Envisia Therapeutics, a privately held biotechnology company that works on ocular therapies. He also served in posts at several ophthalmology-based R&D organizati
10/19/17 - GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Entry into a Material Definitive Agreement
GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement. On October 12, 2017, Galena Biopharma, Inc. (Galena) and Cardinal Health (Cardinal), entered into a settlement agreement and mutual release (Agreement) to which parties agreed to resolve
10/19/17 - NVO : Semaglutide Gets Positive Vote In Favour Of Approval From FDA Panel
WASHINGTON- Novo Nordisk said that the Endocrinologic and Metabolic Drugs Advisory Committee or EMDAC of the US Food and Drug Administration voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. Based on the data included in the New Drug Application for semaglutide, the FDA aske
10/19/17 - Rep. Ted Lieu (D-CA) News Release
WASHINGTON- Today, Congressman Ted W. Lieu issued the following statement after the Food and Drug Administration approved the use of gene therapy for certain types of non-Hodgkin lymphoma. Immunotherapy is a promising and important new area of cancer treatment and advancements in this field have the potential to cure certain cancer patients.
SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Other EventsItem 9.01Other Events On October 17, 2017, Spectrum Pharmaceuticals, Inc. (the Company) announced the oral presentation of interim data from a Phase 2 clinical study evaluating poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (NSCLC) by scientists fromthe MD And
10/19/17 - SPPI Breathes Easy On Trial Results, PTI Awaits Data In Q4, HAIR Keeps Receding
News: The Company presented encouraging interim data from its phase II study evaluating Poziotinib in EGFR Exon 20 mutant non-small cell lung cancer at the 18th IASLC World Conference on Lung Cancer in Japan. The transaction provides Endocyte with 177 Lu-PSMA-617, a phase III-ready prostate cancer drug. Endocyte plans to seek regulatory approval to
10/19/17 - Tucson Tech: Two local companies cited for inventions aiding military [The Arizona Daily Star, Tucson]
Oct. 18 Two Tucson- area companies showcased new technologies to the Department of Defense recently after winning national honors for innovation. Tucson- based NuvOx Pharma, founded by University of Arizona radiology professor Dr. NuvOx already is conducting pre-clinical studies of the drug for treatment of traumatic brain injury with the Navy, u
10/19/17 - Yescarta, second blood cancer gene therapy, approved by FDA [The San Diego Union-Tribune]
Oct. 18 A gene therapy treatment for some hard-to-treat lymphomas was approved Wednesday by the U.S. Food and Drug Administration. It was developed by Kite Pharma, which was recently purchased by Gilead Sciences. The first treatment, Kymriah, or, tisagenlecleucel, was approved Aug. 30 for some pediatric and young adult patients with acute lymphob
10/18/17 - A Personal Letter to the Shareholders from TapImmune's New Chief Executive Officer
TapImmune Inc., a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, announces a letter from the CEO. I feel humbled by the opportunity to speak to you for the first time as CEO of TapImmune. I hope that by describing my perspective on our industry and my vision for TapImmune within it, I mig
10/18/17 - Abbott Reports Third-Quarter 2017 Results
Projected full-year adjusted diluted EPS from continuing operations is now $2.48 to $2.50, which represents an increase at the mid-point of the guidance range. In September, Abbott received U.S. FDA approval for its FreeStyle Libre glucose monitoring system as a replacement 1 for finger stick blood glucose monitoring. This revolutionary technolo
10/18/17 - AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017/ PRNewswire/ AbbVie, a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have entered an immuno-oncology research collaboration. The goal of the collaboration is to i
10/18/17 - Actinium Pharmaceuticals to Present at BIO Investor Forum
Release date- 17102017- NEW YORK- Actinium Pharmaceuticals Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that it will present at the BIO Investor Forum being held on October 16-17th at the Westin St. Francis Hotel in San Francisco, California.
10/18/17 - Agile Therapeutics Presents Additional Twirla Phase 3 SECURE Study Results at NAFFP 2017
Release date- 17102017- PRINCETON, N.J.- Agile Therapeutics Inc.,, a women's healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch, Twirla. Anita Nelson, MD, Professor and Chair of Obstetrics and Gynecology at the College of O
10/18/17 - AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting
LONDON and PHILADELPHIA, Oct. 18, 2017/ PRNewswire/ AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options, presented positive interim analysis of data from the first cohort of its study of AMO-02 in congenital myotonic dystrophy.
10/18/17 - Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie
Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie. LONDON, 18 October 2017: Arix Bioscience plc, a global healthcare and life science company supporting medical innovation, is pleased to note that Harpoon Therapeutics, an Arix Bioscience Group Business, and AbbVie have entered into an immune-oncology research...
10/18/17 - AstraZeneca, Merck Announce FDA Priority Review For Lynparza SNDA
LONDON- AstraZeneca plc and Merck& Co. Inc. announced the US FDA has accepted and granted priority review for a supplemental New Drug Application for the use of Lynparza tablets in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastati
10/18/17 - AstraZenecas Imfinzi cancer drug clears another regulatory hurdle [Tehran Times (Iran)]
AstraZeneca PLCs Imfinzi cancer treatment has cleared another regulatory hurdle after the US Food and Drug Administration accepted a supplemental Biologics License Application for the treatment of certain lung cancer patients. Specifically, the application is for the use of Imfinzi in people with stage III unresectable non-small cell lung cancer...
10/18/17 - Atossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa's Microcatheter Technology
Release date- 17102017- SEATTLE- Atossa Genetics, a clinical stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that the Ernest Mario School of Pharmacy at Rutgers, The State University at New Jersey, plans to conduct a study utilizing Atossa's intraductal..
10/18/17 - BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma
Bergen, Norway, October 18, 2017- BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the randomised Phase 1 b/2 clinical study of BGB324 in combination with either the MAPK inhibitors MEKINIST plus TAFINLAR or the immune checkpoint inhibit
10/18/17 - BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco
BeyondSpring Inc., a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company s Chief Medical Officer and Head of Business Development, Dr. BeyondSpring has advanced its lead asset, Plinabulin, into a global Phase 3 clinical trial for NSCLC treat
10/18/17 - BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced a Phase 1 b/2 study for the treatment of gastric cancer with BL-8040 in combination with atezolizumab, Genentech's anti-PDL1 cancer immunotherapy agent. The clinical study...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement